Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADV-CTLs for Refractory Adenovirus Infection
NCT03266627Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in adenovirus infection, sponsored by New York Medical College. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Incidence of Response to Treatment. Started Nov 2018; status: recruiting.
02
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT03266627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266627.